A.M.M. Eggermont

3.0k total citations
94 papers, 2.1k citations indexed

About

A.M.M. Eggermont is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, A.M.M. Eggermont has authored 94 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Oncology, 33 papers in Molecular Biology and 20 papers in Immunology. Recurrent topics in A.M.M. Eggermont's work include Cutaneous Melanoma Detection and Management (35 papers), Immunotherapy and Immune Responses (17 papers) and Sarcoma Diagnosis and Treatment (14 papers). A.M.M. Eggermont is often cited by papers focused on Cutaneous Melanoma Detection and Management (35 papers), Immunotherapy and Immune Responses (17 papers) and Sarcoma Diagnosis and Treatment (14 papers). A.M.M. Eggermont collaborates with scholars based in Netherlands, Belgium and Germany. A.M.M. Eggermont's co-authors include Johannes H. W. de Wilt, Timo L.M. ten Hagen, Sandra T. van Tiel, Albertus N. van Geel, Stefan Suciu, Johannes H.W. de Wilt, D. Liénard, Joost M. Klaase, Cornelis Verhoef and J.R. Marsden and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

A.M.M. Eggermont

94 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A.M.M. Eggermont Netherlands	26	1.2k	700	602	482	300	94	2.1k
George E. Georges United States	29	585 0.5×	597 0.9×	777 1.3×	312 0.6×	190 0.6×	106	3.1k
Franco Di Filippo Italy	25	847 0.7×	477 0.7×	254 0.4×	306 0.6×	412 1.4×	80	1.9k
Marijo Bilušić United States	22	1.2k 0.9×	471 0.7×	889 1.5×	512 1.1×	190 0.6×	113	2.0k
Ulrika Stierner Sweden	32	1.1k 0.9×	911 1.3×	450 0.7×	422 0.9×	802 2.7×	81	2.6k
Arta M. Monjazeb United States	34	1.6k 1.3×	550 0.8×	1.3k 2.1×	966 2.0×	346 1.2×	123	3.2k
Masoud Azodi United States	32	1.4k 1.1×	809 1.2×	353 0.6×	396 0.8×	531 1.8×	162	3.3k
Panagiota Economopoulou Greece	26	1.4k 1.1×	891 1.3×	392 0.7×	597 1.2×	277 0.9×	105	2.7k
Dennis Cooper United States	27	1.1k 0.9×	461 0.7×	466 0.8×	367 0.8×	459 1.5×	112	2.8k
Christoph Mundhenke Germany	28	906 0.7×	703 1.0×	205 0.3×	403 0.8×	280 0.9×	106	2.3k
J.C. Soria France	21	1.4k 1.1×	1.0k 1.4×	529 0.9×	980 2.0×	226 0.8×	124	2.8k

Countries citing papers authored by A.M.M. Eggermont

Since Specialization

Citations

This map shows the geographic impact of A.M.M. Eggermont's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A.M.M. Eggermont with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A.M.M. Eggermont more than expected).

Fields of papers citing papers by A.M.M. Eggermont

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A.M.M. Eggermont. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A.M.M. Eggermont. The network helps show where A.M.M. Eggermont may publish in the future.

Co-authorship network of co-authors of A.M.M. Eggermont

This figure shows the co-authorship network connecting the top 25 collaborators of A.M.M. Eggermont. A scholar is included among the top collaborators of A.M.M. Eggermont based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A.M.M. Eggermont. A.M.M. Eggermont is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bouwhuis, Marna G., Stefan Suciu, François Salès, et al.. (2010). Prognostic value of serial blood S100B determinations in stage IIB–III melanoma patients: A corollary study to EORTC trial 18952. European Journal of Cancer. 47(3). 361–368. 34 indexed citations

Ijken, Marc G. A. van, Boudewijn van Etten, G. Guetens, et al.. (2005). Balloon catheter hypoxic pelvic perfusion with mitomycin C and melphalan for locally advanced tumours in the pelvic region: A phase I—II trial. European Journal of Surgical Oncology. 31(8). 897–904. 8 indexed citations

Grünhagen, Dirk J., Johannes H. W. de Wilt, Albertus N. van Geel, et al.. (2005). TNF dose reduction in isolated limb perfusion. European Journal of Surgical Oncology. 31(9). 1011–1019. 33 indexed citations

Gool, Arthur R. Van, Heidi H. van Ojik, Wim H.J. Kruit, et al.. (2004). Serum Activity of Prolyl Endopeptidase, but Not of Dipeptidyl Peptidase IV, Is Decreased by Immunotherapy with IFN- α in High-Risk Melanoma Patients. Journal of Interferon & Cytokine Research. 24(7). 411–415. 8 indexed citations

Eggermont, A.M.M., Flávia Brunstein, Dirk J. Grünhagen, & Timo L.M. ten Hagen. (2004). Regional treatment of metastasis: role of regional perfusion. State of the art isolated limb perfusion for limb salvage. Annals of Oncology. 15. iv107–iv112. 11 indexed citations

Hagen, Timo L.M. ten, et al.. (2004). Lack of efficacy of Doxil® in TNF-α-based isolated limb perfusion in sarcoma-bearing rats. British Journal of Cancer. 90(9). 1830–1832. 3 indexed citations

Seynhaeve, Ann L.B., Johannes H. W. de Wilt, Sandra T. van Tiel, A.M.M. Eggermont, & Timo L.M. ten Hagen. (2002). Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity. British Journal of Cancer. 86(7). 1174–1179. 23 indexed citations

Vrouenraets, B. C., A.M.M. Eggermont, Andrew Hart, et al.. (2001). Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- α versus toxicity after melphalan alone. European Journal of Surgical Oncology. 27(4). 390–395. 48 indexed citations

Keilholz, Ulrich, C.J.A. Punt, M. Gore, et al.. (2000). Dacarbazine, cisplatin and IFN-alpha with or without IL-2 in advanced melanoma (EORTC trial 18951). Annals of Oncology. 11. 4. 15 indexed citations

10.

Veen, A.H. van der, Johannes H. W. de Wilt, A.M.M. Eggermont, et al.. (2000). TNF- α augments intratumoural concentrations of doxorubicin in TNF- α -based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. British Journal of Cancer. 82(4). 973–980. 123 indexed citations

11.

Wilt, Johannes H. W. de, Timo L.M. ten Hagen, Gert De Boeck, et al.. (2000). Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. British Journal of Cancer. 82(5). 1000–1003. 158 indexed citations

12.

Rinkes, IHM Borel, et al.. (1997). Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan. British Journal of Cancer. 75(10). 1447–1453. 19 indexed citations

13.

Goey, S.H., Jaap Verweij, R. L. H. Bolhuis, et al.. (1997). Tunnelled central venous catheters yield a low incidence of septicaemia in interleukin-2-treated patients. Cancer Immunology Immunotherapy. 44(5). 301–304. 8 indexed citations

14.

Stam, Tanja C., Mojca Jongen‐Lavrencic, A.M.M. Eggermont, & A. J. G. Swaak. (1996). Effects of isolated limb perfusion with tumour necrosis factor‐alpha on the function of monocytes and T lymphocytes in patients with cancer. European Journal of Clinical Investigation. 26(12). 1085–1091. 9 indexed citations

15.

Kapteijn, B.A.E., Joost M. Klaase, Albertus N. van Geel, A.M.M. Eggermont, & B.B.R. Kroon. (1994). Results of regional isolated perfusion for locally inoperable melanoma of the limbs. Melanoma Research. 4(2). 135–138. 9 indexed citations

16.

Vrouenraets, B. C., Joost M. Klaase, A.N. van Geel, et al.. (1993). Regional Isolated Limb Perfusion in Patients with Malignant Melanoma. Oncology Research and Treatment. 16(3). 163–169. 8 indexed citations

17.

Swaak, A. J. G., D. Liénard, H. Schraffordt Koops, Ferdy J. Lejeune, & A.M.M. Eggermont. (1993). Effects of recombinant tumour necrosis factor (rTNF‐α) in cancer. Observations on the acute phase protein reaction and immunoglobulin synthesis after high dose recombinant TNF‐α administration in isolated limb perfusions in cancer patients. European Journal of Clinical Investigation. 23(12). 812–818. 26 indexed citations

18.

Kleeberg, Ulrich R. & A.M.M. Eggermont. (1993). European Organization for Research and Treatment of Cancer (EORTC)-Melanoma Cooperative Group (MCG) meeting San Miniato, 23–24 April 1993. Melanoma Research. 3(5). 381–381. 2 indexed citations

19.

Eggermont, A.M.M. & Paul H. Sugarbaker. (1988). Efficacy of chemoimmunotherapy with cyclophosphamide, interleukin-2 and lymphokine activated killer cells in an intraperitoneal murine tumour model. British Journal of Cancer. 58(4). 410–414. 17 indexed citations

20.

Tank, Bhupendra, A. Bijma, R. L. Marquet, et al.. (1985). Leukocyte Adherence Inhibition, Natural Killer Cell Activity, Gamma-Interferon Production Capacity and Phytohemagglutinin Response in Patients Treated with Recombinant Leukocyte A Interferon. Oncology. 42(3). 157–163. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact